2025年,皇家菲利普公司打破了预期,提高了全年展望,重申了2045年净零目标。 Royal Philips beat expectations in Q3 2025, raised full-year outlook, and reaffirmed 2045 net-zero goal.

菲利普公司报告了2025年第三季度业绩强于预期,可比销售额增长3%至43亿欧元,调整后EBITA利率扩大至12.3%,这是由于有利的产品组合,成本节约和强的北美业绩所推动的. Royal Philips reported stronger-than-expected third-quarter results for 2025, with comparable sales up 3% to €4.3 billion and adjusted EBITA margin expanding to 12.3%, driven by favorable product mix, cost savings, and strong North American performance. 该公司提出了其全年展望,现在预期其经调整的EBITA差幅的上端。 The company raised its full-year outlook, now expecting the upper end of its adjusted EBITA margin range. 收入增长受到所有部门的推动,个人健康增长占10.9%。 Revenue growth was fueled by all segments, with Personal Health leading at 10.9% growth. Philips重申其全年销售预测为1%-3%,并确认其到2045年的净零目标已得到验证。 Philips reaffirmed its full-year sales forecast of 1%-3% and confirmed its net-zero target by 2045 has been validated. 该公司还强调了AI型医疗创新、新产品推出和正在进行的生产力举措,同时轻描淡写美国关税的影响,并处理与过去回顾相关的持续法律问题。 The company also highlighted AI-powered medical innovations, new product launches, and ongoing productivity initiatives, while downplaying the impact of U.S. tariffs and addressing ongoing legal matters related to a past recall.